NewLimit wants to make an old cell useful again without making it forget what kind of cell it is. Its first test of that idea is headed from the liver lab toward human trials.
A rare mutation pointed to longer, healthier lives. Zoe's bet is that two drug programs can borrow the biology without borrowing the mutation - and its newest mouse data put obesity, muscle preservation and a very expensive clinical test on the same page.